Payment overview · 2025
General Payments
$209.76
11 reported records · 6 companies
Healthcare provider profile · identity verified
Caesar Deiparine, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BEAUMONT, TX · NPI 1174529408
Verified facts
What the public records show
CMS Open Payments records show Caesar Deiparine, M.D. received $209.76 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 34.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.43 | 34.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.58 | 19.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.75 | 15.6% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$27.82 | 13.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.99 | 9.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.19 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $209.76 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $72.43 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $41.58 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $27.82 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 44 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 440 | 131 |
| Atorvastatin Calcium | Atorvastatin Calcium | 337 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 89 |
| Lisinopril | Lisinopril | 239 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 233 | 66 |
| Carvedilol | Carvedilol | 225 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 206 | 107 |
| Metformin Hcl | Metformin Hcl | 202 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 195 | 54 |
| Simvastatin | Simvastatin | 176 | 48 |
| Gabapentin | Gabapentin | 153 | 46 |
| Nifedipine Er | Nifedipine | 139 | 48 |
| Ozempic | Semaglutide | 139 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 39 |
| Montelukast Sodium | Montelukast Sodium | 128 | 44 |
| Azithromycin | Azithromycin | 126 | 101 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 121 | 39 |
| Omeprazole | Omeprazole | 106 | 28 |
| Losartan Potassium | Losartan Potassium | 94 | 30 |
| Farxiga | Dapagliflozin Propanediol | 85 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 26 |
| Alendronate Sodium | Alendronate Sodium | 74 | 17 |
| Meloxicam | Meloxicam | 74 | 26 |
| Furosemide | Furosemide | 71 | 28 |
| Clonidine Hcl | Clonidine Hcl | 68 | 26 |
| Ezetimibe | Ezetimibe | 68 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 62 | 24 |
| Fenofibrate | Fenofibrate | 60 | 15 |
| Glimepiride | Glimepiride | 59 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 19 |
| Potassium Chloride | Potassium Chloride | 52 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 14 |
| Allopurinol | Allopurinol | 50 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 39 |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 15 |
| Eliquis | Apixaban | 44 | 13 |
| Famotidine | Famotidine | 43 | suppressed |
| Repatha Sureclick | Evolocumab | 43 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 38 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 12 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Minoxidil | Minoxidil | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Budesonide | Budesonide | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Prednisone | Prednisone | 26 | 22 |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 14 |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 13 |
| Cefdinir | Cefdinir | 12 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $209.76 · 11 records | Novo Nordisk Inc | Dexcom G6 Transmitter, ELIQUIS, JARDIANCE, MOUNJARO, NURTEC ODT, The Cologuard Plus Collection Kit, VALTOCO, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error